Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CON vs GRDN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: CON 5 – 1 GRDN Matrix Metrics: CON 10 – 0 GRDN

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Guardian Pharmacy Services, Inc. (GRDN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas GRDN carries 35.9/100 (SELL) at $46.94 (31.3x Forward P/E, 6.5% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CON vs GRDN
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66
GRDN NYSE
Guardian Pharmacy Services, Inc.
Retail-Drug Stores And Proprietary Stores
$46.94
+0.58% 1D
Market Cap $3.0B
TTM Revenue $1.46B
Forward P/E 31.3x
Beta / 30D Vol 0.51β · 56% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 8.0 Fund 35.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.3% over 20 days), RSI 57
RSI-14: 57.2 · SMA20: $44.67 · SMA50: $43.04

6-Pillar Scorecard Institutional Category Breakdown (CON 5 – 1 GRDN)

Columns: Metric · CON · GRDN
1. Valuation Multiples CON
Forward P/E 22.0x 31.3x
Trailing P/E 24.5x 39.9x
PEG Ratio N/M N/M
EV / Revenue 3.1x 2.0x
2. Growth & Scale CON
Revenue Growth (YoY) +8.6% -1.7%
Earnings Growth (YoY) +36.4% +88.8%
TTM Revenue (USD) $2.34B $1.46B
Market Cap $5.2B $3.0B
3. Profitability & Quality CON
Gross Margin 29.9% 22.4%
Operating Margin 17.2% 6.5%
Net Profit Margin 9.3% 5.1%
Return on Equity (ROE) 47.2% 32.0%
4. Balance Sheet & Cash Flow CON
Cash Generation (TTM) $257M $96M
Cash Flow Margin 11.0% 6.6%
Net Cash / Leverage $2.04B Net Debt (4.20x D/E) $84M Net Cash
Dividend Yield 0.60% None (0.00%)
5. Options & Positioning CON
Options Structure Phase BREAKOUT SURGE
Current IV / %ile 269.9% (95th %ile) 41.1% (7th %ile)
Put/Call OI Skew 0.79x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat GRDN
OpEx & R&D Intensity 12.7% of Rev ($297M) 15.9% of Rev ($232M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CON (10) vs GRDN (0)
Institutional Metric CON GRDN Criterion Row Edge
Market Capitalization
Scale
$5.2B $3.0B Larger Scale CON
Trailing P/E Ratio
Valuation
24.5x 39.9x Lower Multiple CON
Forward P/E Ratio
Valuation
22.0x 31.3x Lower Multiple CON
Revenue Growth (YoY)
Growth
+8.6% -1.7% Higher Growth CON
Operating Margin (TTM)
Profitability
17.2% 6.5% Higher Margin CON
Net Profit Margin
Profitability
9.3% 5.1% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
47.2% 32.0% Higher ROE CON
52-Week Range Position
Momentum
91% ($19–$44) 84% ($26–$51) Stronger Trend CON
Beta / 30D Volatility
Risk Regime
0.52β · 38% Vol 0.51β · 56% Vol Lower Realized Risk CON
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite CON
Trailing 12M Revenue (USD)
Operating Scale
$2.34B $1.46B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.9% 22.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$257M ($2.04B Net Debt (4.20x D/E)) $96M ($84M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRDN +13.89 pp
CON: +4.68% · GRDN: +18.57%
3M Horizon GRDN +4.93 pp
CON: +19.58% · GRDN: +24.51%
6M Horizon CON +43.25 pp
CON: +65.24% · GRDN: +21.99%
1Y Horizon CON +47.2 pp
CON: +117.58% · GRDN: +70.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CON Revenue GRDN Revenue CON Op. Margin GRDN Op. Margin Margin Leader
FY2022 $1.72B N/A 15.0% N/A CON
FY2023 $1.84B N/A 15.6% N/A CON
FY2024 $1.90B $1.23B 16.0% -5.1% CON
FY2025 $2.16B $1.45B 15.4% 5.0% CON

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRDN SURGE
7d in phase · OBV NEUTRAL
Current IV 41.1%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact GRDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published
GRDN Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.0B market capitalization and 6.5% operating margin.
OpEx & R&D Reinvestment 15.9% of Rev ($232M)
90D Engineering Disclosures 0 Published

Investor FAQ CON vs GRDN Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Guardian Pharmacy Services, Inc. (GRDN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas GRDN carries 35.9/100 (SELL) at $46.94 (31.3x Forward P/E, 6.5% operating margin). Technically, CON sits in a Markup phase (RSI 55.6, BREAKOUT options structure) and GRDN sits in a Markup phase (RSI 57.2, SURGE options structure).

CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with GRDN at -1.7% YoY revenue growth and +88.8% YoY earnings growth on $1.46B TTM revenue (22.4% gross margin, 6.5% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), CON cumulative revenue shifted +25.6% while GRDN shifted +17.9%. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 15.9% of Rev ($232M) (0 disclosures) for GRDN.

CON screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas GRDN trades at 31.3x Forward P/E, 39.9x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (6.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus GRDN (32.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, GRDN carries 41.1% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.51β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.